Courtney Gaughan is an associate in the firm's Business Law Department and a member of its Technology & Life Sciences Group. She joined Goodwin in 2012.
Ms. Gaughan represents public and private companies in all stages of maturity in the technology and life sciences industries. She counsels clients on a wide array of corporate matters, including entity formation, venture financings, public securities offerings, mergers and acquisitions, securities law compliance and strategic transactions.
Ms. Gaughan’s representative matters include:
Capital Markets Transactions
- scPharmaceuticals in its $90 million initial public offering
- Stifel Nicolaus Weisel as an underwriter in Argos Therapeutics $41 million initial public offering
- Repligen Corporation in its $115 million convertible note offering
- Underwriting syndicate in the $64.8 million follow-on financing and subsequent $77 million follow-on financing for Flexion Therapeutics
Mergers and Acquisitions
- Albany Molecular Research Inc. in its sale to The Carlyle Group and GTCR
- iRobot Corporation in the sale of its Defense & Security business to Arlington Capital Partners
- Zalicus Inc. in its sale to Epirus Biopharmaceuticals
- Repligen Corporation in its acquisitions of Refine Technology’s Alternating Tangential Flow (“ATF”) System, Atoll GmbH, TangenX Technology Corporation, and Spectrum, Inc.
- QPID Health in its sale to eviCore healthcare
- Attend, an event software company, in its sale to Event Farm
While attending law school, Ms. Gaughan served as an articles editor on the Florida Law Review and received the Book Award in Business Associations Survey: Business Organizations and Corporations.
University of Florida College of Law